Jonah Feldman

In the SURF302 trial, favorable response rates were seen in the single- and multiple-marker-lesion population, justifying further investigation in the adjuvant bladder cancer setting.

In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Saro Armenian, MD, explains.

OST-HER2, an investigational immunotherapy, yielded favorable overall survival outcomes ahead of an FDA meeting to consider its basis for approval.

Published results from the PARADIGM study of azacitidine/venetoclax showed an event-free survival benefit and lower hemorrhage rates in acute myeloid leukemia.

AUA/SUO's 2026 NMIBC guideline amendment adds 40 statements on risk stratification, surveillance intervals, urinary biomarkers, and emerging BCG-unresponsive therapies.

Etentamig surpassed standard therapy in terms of response rate and progression-free survival in the phase 3 CERVINO trial for relapsed/refractory multiple myeloma.

Daraxonrasib showed dose-dependent objective response rates of 31% to 37% in previously treated RAS-mutant NSCLC, per phase 1/2 trial data published in the New England Journal of Medicine.

Rezatapopt hit a 46% ORR in TP53 Y220C–mutated ovarian cancer in the PYNNACLE trial, with an FDA filing expected in Q1 2027.

The OS findings follow the recent FDA approval of zanidatamab with or without tislelizumab in HER2-positive gastroesophageal cancer.

A JAK inhibitor with a favorable safety profile demonstrated clinical activity in patients with chronic graft-vs-host disease.

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate cancer, as phase 1/2 trial readies 2026 enrollment.

The LRRC15-targeting antibody-drug conjugate will be investigated in a first-in-human trial later this year.

An exploratory analysis from the SECOMBIT trial showed differences in outcomes based on thymidine kinase activity in BRAF-mutated melanoma treated with immunotherapy and targeted therapy.

The MODeFIRe-1 trial of MRT-2359 plus apalutamide will focus on AR mutations in metastatic castration-resistant prostate cancer.

In an interview, Surbhi Sidana, MD, explores the significance of iberdomide's FDA approval and how this agent fits into the growing array of novel multiple myeloma therapies.

In transplant-ineligible or transplant-deferred multiple myeloma, the quadruplet regimen demonstrated sustained benefit in minimal residual disease negativity at nearly 5 years.

A survey of multiple transplant centers found a lack of consistent use of comprehensive screening for chronic GVHD; lead author Laila Alkhouli explained the significance of these findings.

The individualized neoantigen therapy intismeran autogene improved recurrence-free survival over pembrolizumab alone in patients with fully resected melanoma.

Following the FDA approval of vusolimogene oderparepvec plus nivolumab, melanoma specialists are preparing for real-world clinical use while rethinking how to design future intratumoral therapy trials.

FDA reviews OST-HER2 survival data for potential accelerated approval for preventing recurrent metastatic osteosarcoma after lung surgery.

A retrospective cohort study of metastatic castration-sensitive prostate cancer found no difference between the ARPI agents overall, but a signal for survival benefit in those aged 75 or older.

Sagar Lonial, MD, provides commentary on the key questions raised by recent data on lenalidomide maintenance for patients with newly-diagnosed multiple myeloma.

The iberdomide-daratumumab-dexamethasone regimen was approved based on superior MRD negativity rate vs standard of care in relapsed/refractory multiple myeloma.

Three-year follow-up from the single-arm trial that led to talquetamab's approval showed durable progression-free survival and overall survival in heavily pretreated multiple myeloma.

EIK1001, an agonist of TLR 7 and 8, is being investigated in first-line advanced melanoma in combination with pembrolizumab.

NMDP research showed several states and regions at risk of limited access to hematopoietic cell transplantation that can save the lives of patients with cancer.

The FDA gave fast track designation to the anti-TNFR2 agent in combination with pembrolizumab in advanced platinum-resistant ovarian cancer.

The tumor-infiltrating lymphocyte therapy has demonstrated potential for more convenient tissue collection and administration, an unmet need in advanced melanoma.

The FDA approved vusolimogene oderparepvec-wtpg plus nivolumab for PD-1–refractory advanced melanoma after a 10-3 advisory vote in favor of the oncolytic therapy.